Enlivex (ENLV) vs KALA BIO (KALA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
KALA BIO is the larger company by market cap ($5.7 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | KALA |
|---|---|---|
| Share price | $0.255 | $0.2969 |
| Market cap | $5.08M | $5.74M |
| 1-day change | -7.94% | +0.10% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-10.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $95.50 |
| 52-week low | $0.224 | $0.292 |
| Distance from 52-week high | -99.06% | -99.69% |
| Analyst consensus | none | — |
| Avg. price target upside | +31272.55% | — |
| Average volume | 945.30K | 1.46M |
| Shares outstanding | 19.91M | 19.34M |
| Employees | 34 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ENLV vs KALA FAQ
Which is bigger, Enlivex or KALA BIO?
KALA BIO (KALA) is larger, with a market capitalization of $5.74M compared with $5.08M for Enlivex (ENLV).
Are Enlivex and KALA BIO in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.